RBC Capital lowers Amrize stock price target to $32 on cost concerns
RBC Capital cut Amrize's (AMRZ) price target to $32 from $48, citing cost concerns and C-suite turnover. The stock is near its 52-week low, down 36% in six months. Multiple analysts have adjusted targets and ratings, reflecting cautious near-term outlooks. Amrize reports Q3 earnings on October 26, 2026.
How this was made
The 30-second read
Why it matters
Analyst consensus is turning more bearish, with multiple firms cutting targets, indicating broader concerns.
Market read
The series of target cuts signals heightened risk for Amrize, likely prompting short‑term selling pressure.
What to watch
Potential upside from upcoming Q3 earnings if the company beats expectations.
Background
Amrize Ltd is a standalone industrial company facing input‑cost inflation and high executive turnover.
Ticker impact
RBC Capital lowered its price target on Amrize Ltd to $32 ahead of the Q3 earnings release.
likely pressure as the market prices in the lower target
Analyst downgrade and one‑third target reduction signal cost‑inflation concerns and execution risk.
Market effects
Analyst cuts may weigh on other cost‑sensitive industrials.
Limited to U.S. small‑cap investors tracking Amrize.
Minimal global impact.
Counterpoint
Some investors may view the lower target as an entry point if they believe cost pressures are temporary.
Key entities
- analystRBC Capital
Lowered price target to $32, maintaining Underperform.
- analystBofA Securities
Downgraded to Underperform, cut target to $40.
